Production (Stage)
Lexicon Pharmaceuticals, Inc.
LXRX
$0.7667
$0.04976.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,250.63% | 2,479.34% | 884.75% | 792.40% | 1,734.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,250.63% | 2,479.34% | 884.75% | 792.40% | 1,734.13% |
| Cost of Revenue | 46.58% | 20.77% | 3.44% | 1.41% | -2.69% |
| Gross Profit | 13.57% | 30.52% | 4.69% | 4.95% | 7.09% |
| SG&A Expenses | -11.17% | 17.20% | 45.35% | 72.50% | 113.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.12% | 25.88% | 37.92% | 54.27% | 71.94% |
| Operating Income | 10.48% | -8.52% | -35.02% | -51.93% | -70.01% |
| Income Before Tax | 8.41% | -13.15% | -37.08% | -54.61% | -75.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.41% | -13.15% | -37.08% | -54.61% | -75.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.41% | -13.15% | -37.08% | -54.61% | -75.34% |
| EBIT | 10.48% | -8.52% | -35.02% | -51.93% | -70.01% |
| EBITDA | 10.50% | -8.56% | -35.11% | -52.03% | -70.15% |
| EPS Basic | 37.70% | 19.54% | 0.62% | -13.88% | -31.39% |
| Normalized Basic EPS | 41.40% | 23.22% | 1.35% | -13.04% | -30.44% |
| EPS Diluted | 37.70% | 19.54% | 0.62% | -13.88% | -31.39% |
| Normalized Diluted EPS | 41.40% | 23.22% | 1.35% | -13.04% | -30.44% |
| Average Basic Shares Outstanding | 48.50% | 44.76% | 40.51% | 38.11% | 33.86% |
| Average Diluted Shares Outstanding | 48.50% | 44.76% | 40.51% | 38.11% | 33.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |